{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:35:37Z","timestamp":1791495337582,"version":"4.3.4"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.cld.2019.08.002","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T09:27:47Z","timestamp":1572254867000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Epidemiology, Predisposing Factors, and Outcomes of Drug-Induced Liver Injury"],"prefix":"10.1016","volume":"24","author":[{"given":"Einar S.","family":"Bj\u00f6rnsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2019.08.002_bib1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.08.002_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Bjornsson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.08.002_bib3","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.08.002_bib4","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.08.002_bib5","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.cld.2019.08.002_bib6","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/j.gastro.2016.12.016","article-title":"Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study","volume":"152","author":"Nicoletti","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.08.002_bib7","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.01.034","article-title":"Identification of a PTPN22 missense variant as a general genetic risk factor for drug-induced liver injury","author":"Cirulli","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.08.002_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/j.1875-9114.1992.tb04511.x","article-title":"Liver disease associated with diclofenac, naproxen and piroxicam","volume":"12","author":"Jick","year":"1992","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.cld.2019.08.002_bib9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5694\/j.1326-5377.1993.tb137624.x","article-title":"Cholestatic hepatitis associated with flucloxacillin","volume":"158","author":"Derby","year":"1993","journal-title":"Med J Aust"},{"key":"10.1016\/j.cld.2019.08.002_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/j.1875-9114.1993.tb02742.x","article-title":"Liver disorders in patients receiving chlorpromazine or isoniazid","volume":"13","author":"Derby","year":"1993","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cld.2019.08.002_bib11","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/archinte.1996.00440110099013","article-title":"Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid","volume":"156","author":"Garcia Rodriguez","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cld.2019.08.002_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/archinte.1994.00420030117012","article-title":"Acute liver injury associated with nonsteroidal anti-in flammatory drugs and the role of risk factors","volume":"154","author":"Garcia Rodriguez","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cld.2019.08.002_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2004.02133.x","article-title":"Acute and clinically relevant drug-induced liver injury: a population based case-control study","volume":"58","author":"de Abajo","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cld.2019.08.002_bib14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1365-2036.2006.03117.x","article-title":"Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic","volume":"24","author":"De Valle","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2019.08.002_bib15","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/ajg.2012.138","article-title":"A\u00a0prospective nationwide study of drug-induced liver injury in Korea","volume":"107","author":"Suk","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2019.08.002_bib16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1478-3231.2007.01461.x","article-title":"Drug-induced liver injury at an Asian center: a prospective study","volume":"27","author":"Wai","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2019.08.002_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1872-034X.2008.00486.x","article-title":"Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006","volume":"39","author":"Takikawa","year":"2009","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2019.08.002_bib18","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/ajg.2010.287","article-title":"Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis and predictors of mortality","volume":"105","author":"Devarbhavi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2019.08.002_bib19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/MEG.0b013e32835f6889","article-title":"Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients","volume":"25","author":"Zhou","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.08.002_bib20","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/liv.13662","article-title":"Drug induced acute liver failure in children and adults: results of a single-centre study of 128 patients","volume":"38","author":"Devarbhavi","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2019.08.002_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12664-018-0820-6","article-title":"Ayurvedic and herbal medicine-induced liver injury: it is time to wake up and take notice","volume":"37","author":"Devarbhavi","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.cld.2019.08.002_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.08.002_bib23","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bjornsson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.08.002_bib24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40264-017-0547-9","article-title":"The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the state of Delaware","volume":"40","author":"Vega","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.cld.2019.08.002_bib25","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/hep.23937","article-title":"Drug-induced acute liver failure: results of a U.S. multicenter, prospective study","volume":"52","author":"Reuben","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.08.002_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00228-004-0888-z","article-title":"Incidence of drug-induced liver injury in medical inpatients","volume":"61","author":"Meier","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cld.2019.08.002_bib27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2125.2000.00282.x","article-title":"Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals","volume":"50","author":"Bagheri","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cld.2019.08.002_bib28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/(SICI)1099-1557(199907)8:4<275::AID-PDS427>3.0.CO;2-D","article-title":"Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts","volume":"8","author":"Duh","year":"1999","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cld.2019.08.002_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/00365520310000492","article-title":"Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis","volume":"38","author":"Bj\u00f6rnsson","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cld.2019.08.002_bib30","first-page":"1","article-title":"Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States","volume":"101","author":"Vuppalanchi","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2019.08.002_bib31","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2019.08.002_bib32","first-page":"1531","article-title":"Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure","volume":"50","author":"Ohmori","year":"2003","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.cld.2019.08.002_bib33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2796.2007.01818.x","article-title":"Acute liver failure in Sweden: etiology and outcome","volume":"262","author":"Wei","year":"2007","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.cld.2019.08.002_bib34","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/lt.20204","article-title":"Liver transplantation for acute liver failure from drug induced liver injury in the United States","volume":"10","author":"Russo","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2019.08.002_bib35","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/j.gastro.2015.02.050","article-title":"Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system","volume":"148","author":"Goldberg","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.08.002_bib36","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.22895","article-title":"Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and gender","volume":"49","author":"Lucena","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.08.002_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2042098610386281","article-title":"Drug-induced liver injury in older adults","volume":"1","author":"Mitchell","year":"2010","journal-title":"Ther Adv Drug Saf"},{"issue":"5","key":"10.1016\/j.cld.2019.08.002_bib38","article-title":"Case characterization, clinical features and risk factors in drug-induced liver injury","volume":"17","author":"Ort Ortega-Alonso","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cld.2019.08.002_bib39","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0002-9343(80)90443-X","article-title":"Adverse reactions to nitrofurantoin. Analysis of 921 reports","volume":"69","author":"Holmberg","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.cld.2019.08.002_bib40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1378\/chest.128.1.116","article-title":"Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic","volume":"128","author":"Fountain","year":"2005","journal-title":"Chest"},{"issue":"1\u20132","key":"10.1016\/j.cld.2019.08.002_bib41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0168-8278(92)90029-O","article-title":"Liver damage from flucloxacillin, cloxacillin and dicloxacillin","volume":"15","author":"Olsson","year":"1992","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.08.002_bib42","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hep.21324","article-title":"Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain","volume":"44","author":"Lucena","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2019.08.002_bib43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1212\/WNL.37.3.379","article-title":"Valproic acid hepatic fatalities: a retrospective review","volume":"37","author":"Dreifuss","year":"1987","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.cld.2019.08.002_bib44","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.1840220320","article-title":"Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions","volume":"22","author":"Banks","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.08.002_bib45","series-title":"Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver","first-page":"603","author":"Zimmerman","year":"1999"},{"key":"10.1016\/j.cld.2019.08.002_bib46","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.08.002_bib47","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","article-title":"The risk of drug-induced liver injury from Tumor Necrosis Factor (TNF)-alpha-antagonists","volume":"13","author":"Bj\u00f6rnsson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.08.002_bib48","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.cgh.2017.05.027","article-title":"Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids","volume":"15","author":"Bj\u00f6rnsson","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.08.002_bib49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2014.03.045","article-title":"Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6\u00a0months from onset","volume":"147","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.08.002_bib50","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/ajg.2017.215","article-title":"Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians","volume":"112","author":"Chalasani","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2019.08.002_bib51","first-page":"369","article-title":"Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up","volume":"10","author":"Malatjalian","year":"1996","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cld.2019.08.002_bib52","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":"Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment","volume":"46","author":"Rosenberg","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.08.002_bib53","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2019.08.002_bib54","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jhep.2016.05.003","article-title":"Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury","volume":"65","author":"Medina-Caliz","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.08.002_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14740338.1.2.159","article-title":"The rational use of potentially hepatotoxic medications in patients with underlying liver disease","volume":"1","author":"Lewis","year":"2002","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cld.2019.08.002_bib56","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1053\/j.gastro.2004.03.030","article-title":"Are patients with elevated liver tests at increased risk of drug-induced liver injury?","volume":"126","author":"Russo","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.08.002_bib57","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.08.002_bib58","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","article-title":"Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial","volume":"46","author":"Lewis","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.08.002_bib59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","article-title":"Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study","volume":"47","author":"Ekstedt","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.08.002_bib60","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hep.510310129","article-title":"Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection","volume":"31","author":"Wong","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.08.002_bib61","first-page":"1304","article-title":"Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy","volume":"127","author":"Lee","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.cld.2019.08.002_bib62","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1572-0241.2002.05704.x","article-title":"Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United \u2028States","volume":"97","author":"Patel","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2019.08.002_bib63","first-page":"448","article-title":"Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load","volume":"62","author":"Wang","year":"2011","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cld.2019.08.002_bib64","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1440-1746.1997.tb00353.x","article-title":"A\u00a0prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B","volume":"12","author":"Hwang","year":"1997","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.08.002_bib65","doi-asserted-by":"crossref","first-page":"934","DOI":"10.5588\/ijtld.12.0782","article-title":"Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre","volume":"17","author":"Shu","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cld.2019.08.002_bib66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00408-013-9535-8","article-title":"Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis","volume":"192","author":"Liu","year":"2014","journal-title":"Lung"},{"key":"10.1016\/j.cld.2019.08.002_bib67","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus","volume":"157","author":"Ungo","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cld.2019.08.002_bib68","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1097\/00002030-200012220-00011","article-title":"Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection","volume":"14","author":"den Brinker","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2019.08.002_bib69","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00126334-200107010-00017","article-title":"Risk factors for hepato-toxicity in patients treated with highly active antiretroviral therapy","volume":"27","author":"Bonfanti","year":"2001","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.cld.2019.08.002_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00042560-200201010-00005","article-title":"Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection","volume":"29","author":"Aceti","year":"2002","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2019.08.002_bib71","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1086\/381453","article-title":"Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection","volume":"38","author":"Bonacini","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2019.08.002_bib72","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhep.2004.11.017","article-title":"Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era","volume":"42","author":"Kramer","year":"2005","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.08.002_bib73","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.08.002_bib74","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s005350050334","article-title":"Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C","volume":"35","author":"Arase","year":"2000","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cld.2019.08.002_bib75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.hepres.2004.06.002","article-title":"The fluctuation of viral load and serum alanine aminotransferase levels in chronic hepatitis C","volume":"30","author":"ItoH","year":"2004","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2019.08.002_bib76","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-8278(01)00266-5","article-title":"Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and un- treated patients: a long term cohort study","volume":"36","author":"Brunetto","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.08.002_bib77","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1089\/apc.2006.20.817","article-title":"Aminotransferase elevation in HIV\/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs","volume":"20","author":"Jain","year":"2006","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.cld.2019.08.002_bib78","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy\u2019s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury","volume":"147","author":"Robles\u2013Diaz","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.08.002_bib79","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/hep.29283","article-title":"Death and liver transplantation within 2 years of onset of drug-induced liver injury","volume":"66","author":"Hayashi","year":"2017","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326119300522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326119300522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:55:28Z","timestamp":1761069328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326119300522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1089326119300522"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2019.08.002","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology, Predisposing Factors, and Outcomes of Drug-Induced Liver Injury","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2019.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}